Next Article in Journal
Incidence of Post-Operative Pain following a Single-Visit Pulpectomy in Primary Molars Employing Adaptive, Rotary, and Manual Instrumentation: A Randomized Clinical Trial
Next Article in Special Issue
Associations of Three-Dimensional Anthropometric Body Surface Scanning Measurements and Coronary Artery Disease
Previous Article in Journal
Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies
Previous Article in Special Issue
Optimal Heart Rate Control Improves Long-Term Prognosis of Decompensated Heart Failure with Reduced Ejection Fraction
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 59
Issue 2
10.3390/medicina59020354
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Urinary microRNA in Diabetic Kidney Disease: A Literature Review

by
Chin-Chan Lee
1,
Chia-Chun Chen
2,3,
Cheng-Kai Hsu
1,
Yih-Ting Chen
1,
Chun-Yu Chen
1,
Kai-Jie Yang
1,
Ming-Jui Hung
4 and
I-Wen Wu
1,5,*
1
Department of Nephrology, Chang Gung Memorial Hospital, Keelung 204, Taiwan
2
Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan
3
Department of Laboratory Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan
4
Department of Cardiology, Chang Gung Memorial Hospital, Keelung 204, Taiwan
5
College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
*
Author to whom correspondence should be addressed.
Medicina 2023, 59(2), 354; https://doi.org/10.3390/medicina59020354
Submission received: 30 December 2022 / Revised: 31 January 2023 / Accepted: 10 February 2023 / Published: 13 February 2023
(This article belongs to the Special Issue Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights, Mechanisms, and Pharmacotherapies)
Browse Figure
Versions Notes

Abstract

:
Diabetic kidney disease is the most common primary disease of end-stage kidney disease globally; however, a sensitive and accurate biomarker to predict this disease remains awaited. microRNAs are endogenous single-stranded noncoding RNAs that have intervened in different post-transcriptional regulations of various cellular biological functions. Previous literatures have reported its potential role in the pathophysiology of diabetic kidney disease, including regulation of Transforming Growth Factor-β1-mediated fibrosis, extracellular matrix and cell adhesion proteins, cellular hypertrophy, growth factor, cytokine production, and redox system activation. Urinary microRNAs have emerged as a novel, non-invasive liquid biopsy for disease diagnosis. In this review, we describe the available experimental and clinical evidence of urinary microRNA in the context of diabetic kidney disease and discuss the future application of microRNA in routine practice.

Diabetes mellitus (DM) is a major health threat involving 463 million persons globally [1,2]. Diabetic kidney disease (DKD) constitutes the top cause of end-stage kidney disease worldwide [3,4]. The medical burden is complicated by its strong association with cardiovascular diseases, death [5,6], as well as elevated medical financial demand [7]. Improvements in the understanding of pathophysiology and early prediction of DKD remain an unmet clinical need.
Knowledge of systems biology and advances in high-throughput sequencing technology have revolutionized the understanding of the pathophysiology of DKD and biomarker development [8]. Clinical translation of different omic biomarkers for the prediction of DKD remains limited in terms of sample size and validation cohort. An approach that precisely identifies predisposed high-risk DM patients to renal progression is urgently awaited.
Optimal biomarkers have to provide adequate sensitivity and specificity, be obtainable in a non-invasive nature and assay with friendly laboratory skills using minimal time and economical consumption. Urine represents an ideal non-invasive biomarker, mainly for genitourinary diseases, because it is easily collected in large quantities without injury to the patient. In addition to varied types of proteins, the exosomes, which can be secreted by cells of different nephron segments, may also transport protein, mRNA, and microRNA (miRNA) markers produced in conditions of kidney malfunction or structural damage [9]. From them, the urinary exosomes can provide a panoramic view of the whole urinary system.
In this narrative literature review, we examine emerging evidence from experimental and human research that suggest the potential role of urinary miRNA for clinical application in the context of DKD.

1. Introduction of microRNA

The miRNAs are important epigenetic regulators of gene expression that intervene in various cellular processes of health and disease status. Genes encoding miRNAs are situated in the noncoding region or in introns of either protein-coding genes (miR-trons) or noncoding RNA [10]. These are small, less than 70 nucleotide stem–looped structures transcribed by RNA polymerase II located in the nucleus. miRNAs rarely bind to the coding regions of mRNA or genomic DNA, including promoter regions. However, they can actively play a role as regulators of cellular crosstalk by modifying their transcriptional program [11]. Currently, there are more than 38,000 mature sequences of miRNA included in miRbase, and the entry list is still growing [12].
Most miRNAs remain stable and have a prolonged half-life, but other individual miRNAs can experience a rapid decline in certain cellular circumstances because of the existence of specific environmental stimuli or cellular factors [13]. miRNAs are ubiquitous and can be present in different compartments of the body, including blood, urine and other body fluids. To avoid the degradation of miRNA by ribonucleases, they are often packaged in the form of micro-vesicles or exosomes or carried by RNA-binding proteins [14]. The miRNAs are potentially superior biomarkers than proteins and mRNAs because of their stability in body fluids and the high reproducibility by using accurate and sensitive amplification methods. However, the isolation and quantification of miRNAs are technique and time laborious, which limits their applications in routine clinical practice.

2. miRNAs in Kidney Homeostasis

Several miRNAs are expressed primarily in the adult human kidney (such as miR-215, miR-146a and miR-886); other miRNAs (for example, miR-192, miR-194, miR-21, miR-200a, miR-204 and let-7a–g), are increased in the kidney as well as in other organs [15]. This expression is tissue-specific and can be dependent on the developmental stage. Deletion of the miR-17~92 cluster leads to defective embryogenesis, affecting progenitor cells and the development of nephrons. Mice deficient in miR-17~92 are categorized by renal hypodysplasia and cause glomerular damage and proteinuria [16].
miRNAs are involved in different renal cellular processes, glomerular haemodynamia, as well as the maintenance of fluid and electrolyte balance. Other miRNAs in the kidney can also affect renin-expressing juxtaglomerular cells, which leads to damage to these cells. Consequently, plasma renin level decreased, and it was associated with hypotension and renal fibrosis [17]. The miRNAs also can help in the osmolarity homeostasis and have effects on the process of Na+, K+ and Ca2+ regulation in the condition of hypertonic environments [18].

3. Role miRNA in DKD: Murine Experiments

Hyperglycaemia can trigger a complex interplay between metabolic and hemodynamic factors leading to the genesis of various diabetic complications, including DKD. The presence of high glucose concentration has an adverse influence on all renal cell lineages (mesangial cells, tubular cells, podocytes and endothelial cells) and can modulate the expression of miRNAs affecting cellular intercommunication and kidney tissue homeostasis [19].
Numerous studies have demonstrated the difference in the expression of circulating miRNAs throughout the progression of DKD [15]. A high glucose condition affects the expression of miR-29a and miR-29c, leading to the apoptosis of podocytes and the promotion of pro-fibrotic substances [20,21,22]. The hyperglycemia also regulates the expression of miR-25, miR-93 and miR-192, which in turn affects the redox system, vascular endothelial growth factor and tubulointerstitial fibrosis [23,24,25]. A comprehensive description of changes in the expression of 41 miRNAs in different animal studies is summarized in Table 1.

4. Urinary miRNA Research: Human Evidence

Research into miRNA has unveiled obscure puzzles of the pathophysiology of DKD. Furthermore, other investigators have interrogated the clinical utility of these miRNAs for routine practice. Emerging evidence indicates the probable roles of urinary miRNAs as predictors of DKD development or progression [66]. Urine miRNA levels provide a direct reflection of kidney tissue damage. These miRNAs originate from cells and are encapsulated into extracellular vesicles, named exosomes, and are secreted in various biological fluids, including urine. Exosomes can exert paracrine effects and serve as a mediator of intercellular communication. They are stable in biological fluid as well as in paraffin-embedded sections, rendering these exosomes suitable as “liquid biopsy” or biomarkers of specific disease conditions [67]. A number of studies have examined the relationship between urinary microRNA and blood sugar levels. They found that concentrations of various urinary extravesical miRNAs (such as miRNA-941-5p, miRNA 34c-5p and miRNA-208a-3p) were correlated with levels of glycosylated hemoglobin [68]. Table 2 lists changes in the expression of urinary miRNA associated with DKD in clinical research. We identified 141 unique urinary miRNAs associated with DKD. Peculiarly, the direction of expression of specific miRNA differs between types of DM (type 1 vs. 2) and also between distinct patient cohorts (as highlighted in bold). A possible explanation might reside in unclear mechanisms between the two types of DM. In addition, several technical concerns may affect the miRNA profiling, including methods of specimen collection (processing and storage), a fraction of extracted urine (urine, urinary extra-vesicle, extra-vesicle depleted urine fraction), analytic platform (qPCR, microarray, genome-wide profiling by small-RNA sequencing) and artifact contamination [68]. Finally, the cell source of urinary miRNA can arise from any genitourinary tract, and the function of urinary miRNA is not necessarily the same as circulating ones. Sophisticated bioinformatics analysis and network interaction maps are capable of identifying Gene Ontology processes, classification and relevant pathways of target genes in this modern era [66,69]. These approaches may help to decipher the biological functions of urinary miRNA in the pathophysiology of DKD.

5. Performances of Urinary miRNAs as Disease Biomarker

A body of literature attempted to identify potential biomarkers from urine specimens in predicting the degree of kidney damage. Individual miRNAs or a cluster of miRNAs were used as possible biomarkers of DKD with satisfactory prediction performance. Li et al. found that urinary expression of let-7c-5p, miR29c-5p and miR-15b-5p could predict DKD with the area under curves (AUC) of 0.818, 0.774, and 0.818, respectively [70]. Eissa S et al. observed that the AUC of miR-15b, miR-34a, and miR-636 were 0.883, 0.917 and 0.984, respectively, for distinguishing DKD from controls. The panel composed of three miRNAs yielded an AUC of 0.912 [78,81]. The expressed levels of miR-95-3p, miR-185-5p, miR-1246, and miR-631 in urinary sediments can also yield a good accuracy (AUC, 0.863) for differentiating DKD from non-DKD or other disease conditions [88]. Collectively, all this evidence suggests the potential use of urinary miRNAs as non-invasive biomarkers for predicting DKD.

6. Conclusions

Sensitive biomarkers to guide decision-making in the management of DKD remain urgently awaited. Urinary miRNA may represent promising non-invasive, and cheap means with diagnostic or predictive implications in DKD. However, the clinical application is unsatisfactory to date because of inconsistencies between reported data. Most of the research projects reported were discovery experiments with small samples and limitation validation. In addition, the discrepancies may be in part explained by differences in procedures of urine isolation, the proportion of urine fraction (fresh urine, concentrates of extra-vesicles or extra-vesicle depleted fraction) used, heterogeneity in reporting outcome and in the degree of kidney severity (micro vs. macroalbuminuria, intermittent vs. persistent proteinuria). Furthermore, the advances in analytic methodology enabled the discovery of new miRNAs. Recently, the introduction of the sensor-based methodology using labels on magnetic beads can magnify measurement power. The incorporation of the use of spectrophotometry or electrochemistry, rather than direct visualization, can further enhance the quantification accuracy [89] with small sample sizes and limited validation. Consensus and standardization of methodologies applied to retrieve, isolate, store and measure miRNAs may enhance the reproducibility of the study results. Further validation with an extended sample size is warranted to move the field forward clinical translation of urinary miRNA in DKD.

7. Review Criteria

We conducted a narrative review of animal and human studies in published literature from 1 October 2013 until 30 July 2022. The PubMed database was used for searching the scientific literature using the following search terms: “microRNA”, “diabetic kidney disease”, “diabetic nephropathy”, and “urinary”. This narrative literature review primarily focused on original articles written in the English language and published in peer-reviewed journals. The reference lists of included articles were also hand-searched. References were managed using EndNote 20.1.
Independent researchers (CKH and YTC) managed titles and abstracts to identify potentially eligible studies for full-text review. We only included original articles and case series with over two cases in the English language for further assessment. Data extraction was performed in duplicate by two independent reviewers (CCL, KJY). When multiple articles reporting data from the same study population were identified, the most comprehensive data were used. All reported miRNAs are indexed and annotated as a mature sequence of miRNA identified from the miRbase database. Studies were required to provide quantizable data on the expression levels of miRNA, such as fold changes (down-expression, up-expression, not change or absolute value) or area under curves. We contacted the study authors regarding possible incomplete data on miRNA quantities presented in selected publications. The methodological quality of included studies was not assessed in this narrative review because large heterogenicity presented in the testing techniques (ELISA, microarray, q-PCR, sequencing, etc.) and differences in reporting outcomes.
We identified 247 records from the PubMed database for the initial assessment, and only 63 articles were included for full-text review; 40 articles related to animal studies and 23 human research articles, respectively (Figure 1). This literature review included a thorough assessment of 41 miRNA from animal experiments and 141 miRNA from urine samples of DKD patients.

Author Contributions

Conceptualization, C.-C.C. and I.-W.W.; methodology, C.-K.H.; formal analysis, K.-J.Y.; investigation, Y.-T.C.; resources, I.-W.W.; data curation, C.-Y.C. and K.-J.Y.; writing—original draft preparation, C.-C.L.; writing—review and editing, I.-W.W.; supervision, C.-C.C. and M.-J.H.; project administration, K.-J.Y.; funding acquisition, I.-W.W. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Chang Gung Memorial Hospital (CMRPG2C0342, CRRPG2H0124, CRRPG2H0154).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We thank all researchers and clinicians involved in the individual trials.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. WHO. Improving Health Outcomes of People with Diabetes Mellitus: Target Setting to Reduce the Global Burden of Diabetes Mellitus by 2030. 2021. Available online: https://www.who.int/publications/m/item/improving-health-outcomes-of-people-with-diabetes-mellitus (accessed on 30 October 2022).
  2. Federation, I.D. IDF Diabetes Atlas. Ninth edition 2019. Available online: www.diabetesatlas.org (accessed on 13 September 2021).
  3. Alicic, R.Z.; Cox, E.J.; Neumiller, J.J.; Tuttle, K.R. Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 2021, 17, 227–244. [Google Scholar] [CrossRef] [PubMed]
  4. System, U.S.R.D. 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2020.
  5. Webster, A.C.; Nagler, E.V.; Morton, R.L.; Masson, P. Chronic Kidney Disease. Lancet 2017, 389, 1238–1252. [Google Scholar] [CrossRef] [PubMed]
  6. Wen, C.P.; Cheng, T.Y.D.; Tsai, M.K.; Chang, Y.C.; Chan, H.T.; Tsai, S.P.; Chiang, P.H.; Hsu, C.C.; Sung, P.K.; Hsu, Y.H.; et al. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008, 371, 2173–2182. [Google Scholar] [CrossRef] [PubMed]
  7. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020, 395, 709–733. [Google Scholar] [CrossRef]
  8. Betz, B.B.; Jenks, S.J.; Cronshaw, A.D.; Lamont, D.J.; Cairns, C.; Manning, J.R.; Goddard, J.; Webb, D.J.; Mullins, J.J.; Hughes, J.; et al. Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. Kidney Int. 2016, 89, 1125–1135. [Google Scholar] [CrossRef]
  9. Alvarez, M.L.; Khosroheidari, M.; Kanchi Ravi, R.; Distefano, J.K. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012, 82, 1024–1032. [Google Scholar] [CrossRef]
  10. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005, 438, 685–689. [Google Scholar] [CrossRef]
  11. Trionfini, P.; Benigni, A.; Remuzzi, G. microRNAs in kidney physiology and disease. Nat. Rev. Nephrol. 2015, 11, 23–33. [Google Scholar] [CrossRef]
  12. Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2018, 47, D155–D162. [Google Scholar] [CrossRef]
  13. Chandrasekaran, K.; Karolina, D.S.; Sepramaniam, S.; Armugam, A.; Wintour, E.M.; Bertram, J.F.; Jeyaseelan, K. Role of microRNAs in kidney homeostasis and disease. Kidney Int. 2012, 81, 617–627. [Google Scholar] [CrossRef] [Green Version]
  14. Sun, I.O.; Lerman, L.O. Urinary microRNA in kidney disease: Utility and roles. Am. J. Physiol. Renal Physiol. 2019, 316, F785–F793. [Google Scholar] [CrossRef] [PubMed]
  15. Kato, M.; Natarajan, R. Diabetic nephropathy--emerging epigenetic mechanisms. Nat. Rev. Nephrol. 2014, 10, 517–530. [Google Scholar] [CrossRef] [PubMed]
  16. McClelland, A.; Hagiwara, S.; Kantharidis, P. Where are we in diabetic nephropathy: microRNAs and biomarkers? Curr. Opin. Nephrol. Hypertens. 2014, 23, 80–86. [Google Scholar] [CrossRef]
  17. Carney, E.F. Diabetic nephropathy: MiR-23b protects against fibrosis in diabetic nephropathy. Nat. Rev. Nephrol. 2016, 12, 197. [Google Scholar] [PubMed]
  18. Trionfini, P.; Benigni, A. microRNAs as Master Regulators of Glomerular Function in Health and Disease. J. Am. Soc. Nephrol. 2017, 28, 1686–1696. [Google Scholar] [CrossRef]
  19. DeFronzo, R.A.; Reeves, W.B.; Awad, A.S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 2021, 17, 319–334. [Google Scholar] [CrossRef]
  20. Rao, P.V.; Lu, X.; Standley, M.; Pattee, P.; Neelima, G.; Girisesh, G.; Dakshinamurthy, K.V.; Roberts, C.T., Jr.; Nagalla, S.R. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007, 30, 629–637. [Google Scholar] [CrossRef]
  21. Zhou, L.; Xu, D.Y.; Sha, W.G.; Shen, L.; Lu, G.Y.; Yin, X.; Wang, M.J. High glucose induces renal tubular epithelial injury via Sirt1/NF-kappaB/microR-29/Keap1 signal pathway. J. Transl. Med. 2015, 13, 352. [Google Scholar] [CrossRef]
  22. Wang, B.; Komers, R.; Carew, R.; Winbanks, C.E.; Xu, B.; Herman-Edelstein, M.; Koh, P.; Thomas, M.; Jandeleit-Dahm, K.; Gregorevic, P.; et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol. 2012, 23, 252–265. [Google Scholar] [CrossRef]
  23. Putta, S.; Lanting, L.; Sun, G.; Lawson, G.; Kato, M.; Natarajan, R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23, 458–469. [Google Scholar] [CrossRef] [Green Version]
  24. Fu, Y.; Zhang, Y.; Wang, Z.; Wang, L.; Wei, X.; Zhang, B.; Wen, Z.; Fang, H.; Pang, Q.; Yi, F. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am. J. Nephrol. 2010, 32, 581–589. [Google Scholar] [CrossRef] [PubMed]
  25. Long, J.; Wang, Y.; Wang, W.; Chang, B.H.; Danesh, F.R. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J. Biol. Chem. 2010, 285, 23457–23465. [Google Scholar] [CrossRef] [PubMed]
  26. Du, G.; Xiao, M.; Zhang, X.; Wen, M.; Pang, C.; Jiang, S.; Sang, S.; Xie, Y. Alpinia oxyphylla Miq. extract changes miRNA expression profiles in db-/db- mouse kidney. Biol. Res. 2017, 50, 9. [Google Scholar] [CrossRef]
  27. Xiao, F.; Yu, J.; Liu, B.; Guo, Y.; Li, K.; Deng, J.; Zhang, J.; Wang, C.; Chen, S.; Du, Y.; et al. A novel function of microRNA 130a-3p in hepatic insulin sensitivity and liver steatosis. Diabetes 2014, 63, 2631–2642. [Google Scholar] [CrossRef] [PubMed]
  28. Matboli, M.; Eissa, S.; Ibrahim, D.; Hegazy, M.G.A.; Imam, S.S.; Habib, E.K. Caffeic Acid Attenuates Diabetic Kidney Disease via Modulation of Autophagy in a High-Fat Diet/Streptozotocin- Induced Diabetic Rat. Sci. Rep. 2017, 7, 2263. [Google Scholar] [CrossRef]
  29. Qian, X.; Tan, J.; Liu, L.; Chen, S.; You, N.; Yong, H.; Pan, M.; You, Q.; Ding, D.; Lu, Y. microRNA-134-5p promotes high glucose-induced podocyte apoptosis by targeting bcl-2. Am. J. Transl. Res. 2018, 10, 989–997. [Google Scholar]
  30. Bhatt, K.; Lanting, L.L.; Jia, Y.; Yadav, S.; Reddy, M.A.; Magilnick, N.; Boldin, M.; Natarajan, R. Anti-Inflammatory Role of microRNA-146a in the Pathogenesis of Diabetic Nephropathy. J. Am. Soc. Nephrol. 2016, 27, 2277–2288. [Google Scholar] [CrossRef]
  31. Lee, H.W.; Khan, S.Q.; Khaliqdina, S.; Altintas, M.M.; Grahammer, F.; Zhao, J.L.; Koh, K.H.; Tardi, N.J.; Faridi, M.H.; Geraghty, T.; et al. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-Regulation of ErbB4 and Notch-1. J. Biol. Chem. 2017, 292, 732–747. [Google Scholar] [CrossRef]
  32. Wan, R.J.; Li, Y.H. microRNA146a/NAPDH oxidase4 decreases reactive oxygen species generation and inflammation in a diabetic nephropathy model. Mol. Med. Rep. 2018, 17, 4759–4766. [Google Scholar]
  33. Kuwagata, S.; Kume, S.; Chin-Kanasaki, M.; Araki, H.; Araki, S.; Nakazawa, J.; Sugaya, T.; Koya, D.; Haneda, M.; Maegawa, H.; et al. microRNA148b-3p inhibits mTORC1-dependent apoptosis in diabetes by repressing TNFR2 in proximal tubular cells. Kidney Int. 2016, 90, 1211–1225. [Google Scholar] [CrossRef]
  34. Mohan, A.; Singh, R.S.; Kumari, M.; Garg, D.; Upadhyay, A.; Ecelbarger, C.M.; Tripathy, S.; Tiwari, S. Urinary Exosomal microRNA-451-5p Is a Potential Early Biomarker of Diabetic Nephropathy in Rats. PLoS ONE 2016, 11, e0154055. [Google Scholar] [CrossRef] [PubMed]
  35. Xu, P.; Guan, M.P.; Bi, J.G.; Wang, D.; Zheng, Z.J.; Xue, Y.M. High glucose down-regulates microRNA-181a-5p to increase pro-fibrotic gene expression by targeting early growth response factor 1 in HK-2 cells. Cell. Signal. 2017, 31, 96–104. [Google Scholar] [CrossRef] [PubMed]
  36. Kato, M.; Dang, V.; Wang, M.; Park, J.T.; Deshpande, S.; Kadam, S.; Mardiros, A.; Zhan, Y.; Oettgen, P.; Putta, S.; et al. TGF-beta induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci. Signal. 2013, 6, ra43. [Google Scholar] [CrossRef] [PubMed]
  37. Dou, L.; Zhao, T.; Wang, L.; Huang, X.; Jiao, J.; Gao, D.; Zhang, H.; Shen, T.; Man, Y.; Wang, S.; et al. miR-200s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes. J. Biol. Chem. 2013, 288, 22596–22606. [Google Scholar] [CrossRef] [PubMed]
  38. Liu, Z.M.; Zheng, H.Y.; Chen, L.H.; Li, Y.L.; Wang, Q.; Liao, C.F.; Li, X.W. Low expression of miR-203 promoted diabetic nephropathy via increasing TLR4. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 5627–5634. [Google Scholar] [PubMed]
  39. Zhang, Z.; Peng, H.; Chen, J.; Chen, X.; Han, F.; Xu, X.; He, X.; Yan, N. microRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009, 583, 2009–2014. [Google Scholar] [CrossRef]
  40. Wang, J.; Gao, Y.; Ma, M.; Li, M.; Zou, D.; Yang, J.; Zhu, Z.; Zhao, X. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem. Biophys. 2013, 67, 537–546. [Google Scholar] [CrossRef]
  41. Chen, X.; Zhao, L.; Xing, Y.; Lin, B. Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression. Biomed. Pharmacother. 2018, 108, 7–14. [Google Scholar] [CrossRef]
  42. Zhong, X.; Chung, A.C.; Chen, H.Y.; Dong, Y.; Meng, X.M.; Li, R.; Yang, W.; Hou, F.F.; Lan, H.Y. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013, 56, 663–674. [Google Scholar] [CrossRef]
  43. Wang, J.Y.; Gao, Y.B.; Zhang, N.; Zou, D.W.; Wang, P.; Zhu, Z.Y.; Li, J.Y.; Zhou, S.N.; Wang, S.C.; Wang, Y.Y.; et al. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol. Cell. Endocrinol. 2014, 392, 163–172. [Google Scholar] [CrossRef]
  44. Lai, J.Y.; Luo, J.; O’Connor, C.; Jing, X.; Nair, V.; Ju, W.; Randolph, A.; Ben-Dov, I.Z.; Matar, R.N.; Briskin, D.; et al. microRNA-21 in glomerular injury. J. Am. Soc. Nephrol. 2015, 26, 805–816. [Google Scholar] [CrossRef] [PubMed]
  45. Wang, J.; Duan, L.; Tian, L.; Liu, J.; Wang, S.; Gao, Y.; Yang, J. Serum miR-21 may be a Potential Diagnostic Biomarker for Diabetic Nephropathy. Exp. Clin. Endocrinol. Diabetes 2016, 124, 417–423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Shao, Y.; Lv, C.; Wu, C.; Zhou, Y.; Wang, Q. Mir-217 promotes inflammation and fibrosis in high glucose cultured rat glomerular mesangial cells via Sirt1/HIF-1alpha signaling pathway. Diabetes Metab. Res. Rev. 2016, 32, 534–543. [Google Scholar] [CrossRef] [PubMed]
  47. Yang, H.; Wang, Q.; Li, S. microRNA-218 promotes high glucose-induced apoptosis in podocytes by targeting heme oxygenase-1. Biochem. Biophys. Res. Commun. 2016, 471, 582–588. [Google Scholar] [CrossRef] [PubMed]
  48. Li, X.; Zeng, L.; Cao, C.; Lu, C.; Lian, W.; Han, J.; Zhang, X.; Zhang, J.; Tang, T.; Li, M. Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy. Exp. Cell Res. 2017, 350, 327–335. [Google Scholar] [CrossRef] [PubMed]
  49. Dey, N.; Bera, A.; Das, F.; Ghosh-Choudhury, N.; Kasinath, B.S.; Choudhury, G.G. High glucose enhances microRNA-26a to activate mTORC1 for mesangial cell hypertrophy and matrix protein expression. Cell. Signal. 2015, 27, 1276–1285. [Google Scholar] [CrossRef]
  50. Zheng, Z.; Guan, M.; Jia, Y.; Wang, D.; Pang, R.; Lv, F.; Xiao, Z.; Wang, L.; Zhang, H.; Xue, Y. The coordinated roles of miR-26a and miR-30c in regulating TGFbeta1-induced epithelial-to-mesenchymal transition in diabetic nephropathy. Sci. Rep. 2016, 6, 37492. [Google Scholar] [CrossRef]
  51. Chen, H.Y.; Zhong, X.; Huang, X.R.; Meng, X.M.; You, Y.; Chung, A.C.; Lan, H.Y. microRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 2014, 22, 842–853. [Google Scholar] [CrossRef]
  52. Sun, S.F.; Tang, P.M.K.; Feng, M.; Xiao, J.; Huang, X.R.; Li, P.; Ma, R.C.W.; Lan, H.Y. Novel lncRNA Erbb4-IR Promotes Diabetic Kidney Injury in db/db Mice by Targeting miR-29b. Diabetes 2018, 67, 731–744. [Google Scholar] [CrossRef]
  53. Lin, C.L.; Lee, P.H.; Hsu, Y.C.; Lei, C.C.; Ko, J.Y.; Chuang, P.C.; Huang, Y.T.; Wang, S.Y.; Wu, S.L.; Chen, Y.S.; et al. microRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J. Am. Soc. Nephrol. 2014, 25, 1698–1709. [Google Scholar] [CrossRef]
  54. Higuchi, C.; Nakatsuka, A.; Eguchi, J.; Teshigawara, S.; Kanzaki, M.; Katayama, A.; Yamaguchi, S.; Takahashi, N.; Murakami, K.; Ogawa, D.; et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes. Metabolism 2015, 64, 489–497. [Google Scholar] [CrossRef]
  55. Tsai, Y.C.; Kuo, P.L.; Hung, W.W.; Wu, L.Y.; Wu, P.H.; Chang, W.A.; Kuo, M.C.; Hsu, Y.L. Angpt2 Induces Mesangial Cell Apoptosis through the microRNA-33-5p-SOCS5 Loop in Diabetic Nephropathy. Mol. Ther. Nucleic Acids 2018, 13, 543–555. [Google Scholar] [CrossRef] [Green Version]
  56. Liu, X.D.; Zhang, L.Y.; Zhu, T.C.; Zhang, R.F.; Wang, S.L.; Bao, Y. Overexpression of miR-34c inhibits high glucose-induced apoptosis in podocytes by targeting Notch signaling pathways. Int. J. Clin. Exp. Pathol. 2015, 8, 4525–4534. [Google Scholar] [PubMed]
  57. Zhang, L.; He, S.; Guo, S.; Xie, W.; Xin, R.; Yu, H.; Yang, F.; Qiu, J.; Zhang, D.; Zhou, S.; et al. Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1. J. Diabetes Complicat. 2014, 28, 259–264. [Google Scholar] [CrossRef] [PubMed]
  58. Xue, M.; Li, Y.; Hu, F.; Jia, Y.J.; Zheng, Z.J.; Wang, L.; Xue, Y.M. High glucose up-regulates microRNA-34a-5p to aggravate fibrosis by targeting SIRT1 in HK-2cells. Biochem. Biophys. Res. Commun. 2018, 498, 38–44. [Google Scholar] [CrossRef] [PubMed]
  59. Sun, Y.; Peng, R.; Peng, H.; Liu, H.; Wen, L.; Wu, T.; Yi, H.; Li, A.; Zhang, Z. miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy. Mol. Cell Endocrinol. 2016, 433, 75–86. [Google Scholar] [CrossRef] [PubMed]
  60. Katta, A.; Thulluri, S.; Manne, N.D.; Addagarla, H.S.; Arvapalli, R.; Nalabotu, S.K.; Gadde, M.; Rice, K.M.; Blough, E.R. Overload induced heat shock proteins (HSPs), MAPK and miRNA (miR-1 and miR133a) response in insulin-resistant skeletal muscle. Cell. Physiol. Biochem. 2013, 31, 219–229. [Google Scholar] [CrossRef]
  61. Badal, S.S.; Wang, Y.; Long, J.; Corcoran, D.L.; Chang, B.H.; Truong, L.D.; Kanwar, Y.S.; Overbeek, P.A.; Danesh, F.R. miR-93 regulates Msk2-mediated chromatin remodelling in diabetic nephropathy. Nat. Commun. 2016, 7, 12076. [Google Scholar] [CrossRef] [PubMed]
  62. Peng, R.; Liu, H.; Peng, H.; Zhou, J.; Zha, H.; Chen, X.; Zhang, L.; Sun, Y.; Yin, P.; Wen, L.; et al. Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1. Gene 2015, 570, 57–63. [Google Scholar] [CrossRef]
  63. Zhou, J.; Peng, R.; Li, T.; Luo, X.; Peng, H.; Zha, H.; Yin, P.; Wen, L.; Zhang, Z. A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene 2013, 527, 456–461. [Google Scholar] [CrossRef]
  64. Park, J.T.; Kato, M.; Lanting, L.; Castro, N.; Nam, B.Y.; Wang, M.; Kang, S.W.; Natarajan, R. Repression of let-7 by Transforming Growth Factor-beta1-induced Lin28 up-regulates collagen expression in glomerular mesangial cells under diabetic conditions. Am. J. Physiol. Renal Physiol. 2014, 307, F1390–F1403. [Google Scholar] [CrossRef] [PubMed]
  65. Wang, B.; Jha, J.C.; Hagiwara, S.; McClelland, A.D.; Jandeleit-Dahm, K.; Thomas, M.C.; Cooper, M.E.; Kantharidis, P. Transforming growth factor-beta1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 2014, 85, 352–361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Park, S.; Kim, O.H.; Lee, K.; Park, I.B.; Kim, N.H.; Moon, S.; Im, J.; Sharma, S.P.; Oh, B.C.; Nam, S.; et al. Plasma and urinary extracellular vesicle microRNAs and their related pathways in diabetic kidney disease. Genomics 2022, 114, 110407. [Google Scholar] [CrossRef]
  67. Sinha, N.; Kumar, V.; Puri, V.; Nada, R.; Rastogi, A.; Jha, V.; Puri, S. Urinary exosomes: Potential biomarkers for diabetic nephropathy. Nephrology 2020, 25, 881–887. [Google Scholar] [CrossRef] [PubMed]
  68. Ghai, V.; Wu, X.; Bheda-Malge, A.; Argyropoulos, C.P.; Bernardo, J.F.; Orchard, T.; Galas, D.; Wang, K. Genome-wide Profiling of Urinary Extracellular Vesicle microRNAs Associated With Diabetic Nephropathy in Type 1 Diabetes. Kidney Int. Rep. 2018, 3, 555–572. [Google Scholar] [CrossRef]
  69. Li, X.; Xu, R.; Liu, X.; Xu, L.; Xue, M.; Cheng, Y.; Li, T.; Yu, X.; Wang, Y.; Li, C.; et al. Urinary miR-3137 and miR-4270 as potential biomarkers for diabetic kidney disease. J. Clin. Lab. Anal. 2020, 34, e23549. [Google Scholar] [CrossRef] [PubMed]
  70. Li, W.; Yang, S.; Qiao, R.; Zhang, J. Potential Value of Urinary Exosome-Derived let-7c-5p in the Diagnosis and Progression of Type II Diabetic Nephropathy. Clin. Lab. 2018, 64, 709–718. [Google Scholar] [CrossRef]
  71. Prabu, P.; Rome, S.; Sathishkumar, C.; Gastebois, C.; Meugnier, E.; Mohan, V.; Balasubramanyam, M. microRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the ‘Asian Indian phenotype’. Diabetes Metab. 2019, 45, 276–285. [Google Scholar] [CrossRef]
  72. Argyropoulos, C.; Wang, K.; McClarty, S.; Huang, D.; Bernardo, J.; Ellis, D.; Orchard, T.; Galas, D.; Johnson, J. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS ONE 2013, 8, e54662. [Google Scholar] [CrossRef]
  73. González-Palomo, A.K.; Pérez-Vázquez, F.J.; Méndez-Rodríguez, K.B.; Ilizaliturri-Hernández, C.A.; Cardona-Alvarado, M.I.; Flores-Nicasio, M.V.; Kornhauser, C.; Malacara, J.M.; Figueroa-Vega, N. Profile of urinary exosomal microRNAs and their contribution to diabetic kidney disease through a predictive classification model. Nephrology 2022, 27, 484–493. [Google Scholar] [CrossRef]
  74. Osipova, J.; Fischer, D.C.; Dangwal, S.; Volkmann, I.; Widera, C.; Schwarz, K.; Lorenzen, J.M.; Schreiver, C.; Jacoby, U.; Heimhalt, M.; et al. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: A cross-sectional cohort study. J. Clin. Endocrinol. Metab. 2014, 99, E1661–E1665. [Google Scholar] [CrossRef] [PubMed]
  75. Zhao, Y.; Shen, A.; Guo, F.; Song, Y.; Jing, N.; Ding, X.; Pan, M.; Zhang, H.; Wang, J.; Wu, L.; et al. Urinary Exosomal MiRNA-4534 as a Novel Diagnostic Biomarker for Diabetic Kidney Disease. Front. Endocrinol. 2020, 11, 590. [Google Scholar] [CrossRef] [PubMed]
  76. Barutta, F.; Tricarico, M.; Corbelli, A.; Annaratone, L.; Pinach, S.; Grimaldi, S.; Bruno, G.; Cimino, D.; Taverna, D.; Deregibus, M.C.; et al. Urinary Exosomal microRNAs in Incipient Diabetic Nephropathy. PLoS ONE 2013, 8, e73798. [Google Scholar] [CrossRef] [PubMed]
  77. Lee, W.C.; Li, L.C.; Ng, H.Y.; Lin, P.T.; Chiou, T.T.; Kuo, W.H.; Lee, C.T. Urinary Exosomal microRNA Signatures in Nephrotic, Biopsy-Proven Diabetic Nephropathy. J. Clin. Med. 2020, 9, 1220. [Google Scholar] [CrossRef]
  78. Eissa, S.; Matboli, M.; Bekhet, M.M. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis. Biomed. Pharmacother. 2016, 83, 92–99. [Google Scholar] [CrossRef] [PubMed]
  79. Szeto, C.C.; Ching-Ha, K.B.; Ka-Bik, L.; Mac-Moune, L.F.; Cheung-Lung, C.P.; Gang, W.; Kai-Ming, C.; Kam-Tao, L.P. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Markers 2012, 33, 137–144. [Google Scholar] [CrossRef]
  80. Xie, Y.; Jia, Y.; Cuihua, X.; Hu, F.; Xue, M.; Xue, Y. Urinary Exosomal microRNA Profiling in Incipient Type 2 Diabetic Kidney Disease. J. Diabetes Res. 2017, 2017, 6978984. [Google Scholar] [CrossRef]
  81. Eissa, S.; Matboli, M.; Aboushahba, R.; Bekhet, M.M.; Soliman, Y. Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease. J. Diabetes Complicat. 2016, 30, 1585–1592. [Google Scholar] [CrossRef]
  82. An, Y.; Zhang, C.; Xu, F.; Li, W.; Zeng, C.; Xie, L.; Liu, Z. Increased urinary miR-196a level predicts the progression of renal injury in patients with diabetic nephropathy. Nephrol. Dial. Transpl. 2020, 35, 1009–1016. [Google Scholar] [CrossRef]
  83. El-Samahy, M.H.; Adly, A.A.; Elhenawy, Y.I.; Ismail, E.A.; Pessar, S.A.; Mowafy, M.E.; Saad, M.S.; Mohammed, H.H. Urinary miRNA-377 and miRNA-216a as biomarkers of nephropathy and subclinical atherosclerotic risk in pediatric patients with type 1 diabetes. J. Diabetes Complicat. 2018, 32, 185–192. [Google Scholar] [CrossRef]
  84. Peng, H.; Zhong, M.; Zhao, W.; Wang, C.; Zhang, J.; Liu, X.; Li, Y.; Paudel, S.D.; Wang, Q.; Lou, T. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. PLoS ONE 2013, 8, e82607. [Google Scholar] [CrossRef] [PubMed]
  85. Guo, J.; Li, J.; Zhao, J.; Yang, S.; Wang, L.; Cheng, G.; Liu, D.; Xiao, J.; Liu, Z.; Zhao, Z. MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin. Sci. Rep. 2017, 7, 2314. [Google Scholar] [CrossRef]
  86. Argyropoulos, C.; Wang, K.; Bernardo, J.; Ellis, D.; Orchard, T.; Galas, D.; Johnson, J.P. Urinary microRNA Profiling Predicts the Development of Microalbuminuria in Patients with Type 1 Diabetes. J. Clin. Med. 2015, 4, 1498–1517. [Google Scholar] [CrossRef] [PubMed]
  87. Delic, D.; Eisele, C.; Schmid, R.; Baum, P.; Wiech, F.; Gerl, M.; Zimdahl, H.; Pullen, S.S.; Urquhart, R. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients. PLoS ONE 2016, 11, e0150154. [Google Scholar] [CrossRef] [PubMed]
  88. Han, Q.; Zhang, Y.; Jiao, T.; Li, Q.; Ding, X.; Zhang, D.; Cai, G.; Zhu, H. Urinary sediment microRNAs can be used as potential noninvasive biomarkers for diagnosis, reflecting the severity and prognosis of diabetic nephropathy. Nutr. Diabetes 2021, 11, 24. [Google Scholar] [CrossRef] [PubMed]
  89. Ngamdee, T.; Chalermwatanachai, T.; Siriwan, C.; Warachit, O.; Rijiravanich, P.; Surareungchai, W. Target amplification-free detection of urinary microRNA for diabetic nephropathy diagnosis with electrocatalytic reaction. Anal. Bioanal. Chem. 2022, 414, 5695–5707. [Google Scholar] [CrossRef] [PubMed]
Medicina 59 00354 g001 550
Figure 1. Flow chart of literature search and selection.
Figure 1. Flow chart of literature search and selection.
Medicina 59 00354 g001
Table
Table 1. miRNA implicated in the diabetic animal model.
Table 1. miRNA implicated in the diabetic animal model.
Mature Sequence of miRNASpeciesExperimental ModelExpressionNumber
of Study		References
hsa-let-7i-5pMouseDb miceUp1[26]
hsa-miR-129-1-3pMouseDb miceDown1[26]
hsa-miR-130a-3pMouse, cellDb mice, HepG2 cellsUp1[27]
hsa-miR-133bRatHigh-Fat Diet/Streptozotocin-Induced Diabetic RatUp1[28]
hsa-miR-134-5pMouse, cell C57BL/KsJ db mice, Db/Db mice, podocytesUp1[29]
hsa-miR-146a-5pMouse, cellC57BL/6J, miR-146a−/− mice, Podocytes, HK-2 human kidney cells, Db mice, peritoneal macrophagesUp, Down3[30,31,32]
hsa-miR-148b-3pRat, cellProximal tubular cellsDown1[33]
hsa-miR-16-5pRatMale Wistar ratsUp1[34]
hsa-miR-181a-5pRat, cellHK-2 cells, Otsuka-Long-Evans-Tokushima-Fatty ratsDown1[35]
hsa-miR-192-5pMouseDb mice, Ets-1–deficient miceUp1[36]
hsa-miR-200c-3pMouse, cellDb mice, M4200 cellsDown3[26,37,38]
hsa-miR-21-5pMouse, rat, cellC57BI/6J mice, miR-21-KO mice, DBA/2J mice, Db mice, kk-ay mice, epithelial-to-mesenchymal, podocytesUp, Down7[39,40,41,42,43,44,45]
hsa-miR-217-5pCellGlomerular mesangial cellsUp1[46]
hsa-miR-218-5pMouse, cellDb mice, podocytesUp, Down2[26,47]
hsa-miR-23cRat, cellHK-2 cellsDown1[48]
hsa-miR-26a-5pRat, cellOLETF rats, NRK-52E cells, glomerular, mesangial cells, podocytes, proximal tubular epithelial cellsUp, Down2[49,50]
hsa-miR-29a-3pMouse, cellDb mice, Smad3-knockout (KO) db mice, mouse embryonic fibroblasts, NRK52E cells, mesangial cellsDown2[51,52]
hsa-miR-29a-5pMouseMale FVB miceDown1[53]
hsa-miR-29c-3pMouseDb miceDown1[26]
hsa-miR-30a-5pRatHigh-Fat Diet/Streptozotocin-Induced Diabetic RatUp1[28]
hsa-miR-335-5pMouse Male C57BL/6J miceUp1[54]
hsa-miR-33a-5pMouse, cellDb mice, MMCs (CRL1927) and HEK293 cellsDown1[55]
hsa-miR-342-5pRatHigh-Fat Diet/Streptozotocin-Induced Diabetic RatUp1[28]
hsa-miR-34a-5pMouse, cellDb mice, mesangial cells, HK-2cells, podocytesDown3[56,57,58]
hsa-miR-375-5pMouseMale C57BL/6J miceUp1[54]
hsa-miR-378dMouseDb miceUp1[26]
hsa-miR-451aMouse, ratDb mice, male Wistar ratsDown2[34,59]
hsa-miR-7977MouseDb miceDown1[26]
hsa-miR-92b-5pRatLean Zucker, obese Zucker ratsDown1[60]
hsa-miR-93-5pMouse, cellPod-iCreERT2 mice, podocytes Down1[61]
hsa-miR-99b-5pMouse, rat, cellDb mice, mesangial cells, proximal tubular epithelial cellsDown4[62,63,64,65]
miRNAs are annotated as a mature sequence of miRNA identified from the miRbase database.
Table
Table 2. Urinary miRNA implicated in human studies related to diabetic kidney disease.
Table 2. Urinary miRNA implicated in human studies related to diabetic kidney disease.
Mature Sequence of miRNASampleDM TypePatient
Number		Urinary Expression
in DKD		References
has-let-7a-3pBlood/Urine227 Down [66]
hsa-let-7c-5pUrine263Up[70]
hsa-let-7f-1-3p Blood/Urine227 Down [66]
hsa-let-7i-5pUrine2160Up[71]
hsa-miR-106b-3p Blood/Urine227 Down [66]
hsa-miR-10a-5pUrine148Up vs. PMA[68]
hsa-miR-10b-5pUrine148Up vs. PMA[68]
hsa-miR-1224-3pUrine140Up[72]
hsa-miR-122-5pUrine148Up[68]
hsa-miR-126Urine292 Up [73]
hsa-miR-126-5pUrine/blood1147Down[74]
hsa-miR-1275Urine26 Up [75]
hsa-miR-1307-3pUrine148Down[68]
hsa-miR-130a-3pUrine148Up[68]
hsa-miR-130a-5pTissue/Urine124Up[76]
hsa-miR-133a-3pUrine148Up[68]
hsa-miR-133a-3pUrine26Down[77]
hsa-miR-133bUrine2220Up[78]
hsa-miR-135b-5pUrine2160Up[71]
hsa-miR-141-3pUrine140 + 48Up[68,72]
hsa-miR-142-3pUrine148Up[68]
hsa-miR-145-5pTissue/Urine124Up[76]
hsa-miR-146 Urine292 Up [73]
hsa-miR-148a-3pUrine148Up[68]
hsa-miR-148b-3pUrine256Down[79]
hsa-miR-150-3p Urine26 Up [77]
hsa-miR-150-5pUrine280Up[80]
hsa-miR-152-3pUrine148Up[68]
hsa-miR-153-3Urine26Down[77]
hsa-miR-155 Urine292 Up [73]
hsa-miR-155-5pTissue/Urine124Down[76]
hsa-miR-1587Urine26 Up [75]
hsa-miR-15a-5pUrine280Down[80]
hsa-miR-15b-5pUrine2232 + 63 + 160Up/Down/Down[70,71,81]
hsa-miR-17-5pUrine256Down[79]
hsa-miR-17-5pUrine140Up[72]
hsa-miR-181a-5pUrine148Up[68]
hsa-miR-183-5pUrine148Up[68]
hsa-miR-188-3pUrine140Down[72]
hsa-miR-188-5pUrine148Down[68]
hsa-miR-188-5pUrine26Up [77]
hsa-miR-190a-5p Blood/Urine227 Down [66]
hsa-miR-1912Urine140Up[72]
hsa-miR-1913Urine140UP[72]
hsa-miR-192-5pUrine256Down[79]
hsa-miR-192-5pUrine148Up[68]
hsa-miR-193b-5p Urine26 Down [69]
hsa-miR-196aUrine2209 UP [82]
hsa-miR-197-3pUrine2160Down[71]
hsa-miR-197-3pUrine148Down[68]
hsa-miR-200a-3pUrine148Up[68]
hsa-miR-200c-3pUrine148Up[68]
hsa-miR-2117Urine26 Up [75]
hsa-miR-214-3pUrine140UP[72]
hsa-miR-21-5pUrine256Down[79]
hsa-miR-21-5pUrine/blood1147Up[74]
hsa-miR-216a-5pUrine256Down[79]
hsa-miR-216a-5pUrine150Down[83]
hsa-miR-217-5pUrine256Down[79]
hsa-miR-219a-3pUrine26 Up [75]
hsa-miR-221-3pUrine140Down[72]
hsa-miR-222-3pUrine148 + 40Up[68,72]
hsa-miR-22-3pUrine148Up[68]
hsa-miR-23cUrine26 Up [77]
hsa-miR-24-3pUrine2160Up[71]
hsa-miR-27b-3pUrine2160Down[71]
hsa-miR-29a-3pUrine283NC[84]
hsa-miR-29a-5pUrine283Up[84]
hsa-miR-29b-1-5pUrine140Up[72]
hsa-miR-29c-3pUrine2220 + 56 + 63Up/Up/Down[70,78,79]
hsa-miR-29c-3pUrine148Up[68]
hsa-miR-29c-5pUrine283NC[84]
hsa-miR-29c-5pTissue/Blood/Urine227 + 16Down[66,85]
hsa-miR-30a-3pUrine2160Up[71]
hsa-miR-30a-5pUrine148 + 27Up/Down[68,86]
hsa-miR-30b-5p Blood/Urine227 Down [66]
hsa-miR-30c-5p Blood/Urine227Down [66]
hsa-miR-30d-5p Blood/Urine227 Down [66]
hsa-miR-30e-3p Blood/Urine227 Down [66]
hsa-miR-3137 Urine26 Down [69]
hsa-miR-31-5pUrine148Up[68]
hsa-miR-3168Urine148Down[68]
hsa-miR-3184-3pUrine148Up[68]
hsa-miR-320b Blood/Urine227 Up [66]
hsa-miR-320cUrine241Up[87]
hsa-miR-320eUrine26 Up [77]
hsa-miR-323b-5pUrine140Down [72]
hsa-miR-331-3p Blood/Urine227 Down [66]
hsa-miR-335-5pUrine140Up[72]
hsa-miR-339-3pUrine148Up[68]
hsa-miR-342-3pUrine148Up[68]
hsa-miR-342-5pUrine2220Up[78]
hsa-miR-34a-5pUrine2232Up[81]
hsa-miR-362-3pUrine280Up[80]
hsa-miR-362-5pUrine148Down[68]
hsa-miR-363-3pUrine127Down[86]
hsa-miR-3677-3pUrine26 Up [77]
hsa-miR-373-5pUrine140Down[72]
hsa-miR-375-5pUrine2160Down[71]
hsa-miR-377-5pUrine150Up[83]
hsa-miR-377-5pUrine256Up[79]
hsa-miR-424-3pUrine148Down[68]
hsa-miR-424-5pTissue/Urine140 + 24 + 27Up/Down/Down[72,76,86]
hsa-miR-4270 Urine26 Up [69]
hsa-miR-4286Urine148Down[68]
hsa-miR-429Urine140UP[72]
hsa-miR-433Urine140Up[72]
hsa-miR-4491 Urine26 Up [75]
hsa-miR-4507Urine26 Up [75]
hsa-miR-4516Urine26 Up [75]
hsa-mir-453Urine140Down (Up in persistent microalbuminuria)[72]
hsa-miR-4534Urine26 Up [75]
hsa-miR-4687-3pUrine26 Up [75]
hsa-miR-486-3pUrine140Up[72]
hsa-miR-486-5pUrine127Up[86]
hsa-miR-495-5pUrine127Down[86]
hsa-miR-498Urine26 Up [75]
hsa-miR-5007-3pUrine26 Up [75]
hsa-miR-500a-5pUrine2160Down[71]
hsa-miR-5088-5pUrine26 Up [75]
hsa-miR-5091Urine26 Up [75]
hsa-miR-516b-5p, Urine26 Up [75]
hsa-miR-520hUrine140Down[72]
hsa-miR-524-5pUrine140 + 27Down/Down[72,86]
hsa-miR-548ah-3p Urine26 Up [77]
hsa-miR-548pUrine26 Up [77]
hsa-miR-552-5pUrine140Up[72]
hsa-miR-589-5pUrine140Down[72]
hsa-miR-6068Urine241Up[87]
hsa-miR-6076Urine241NC[87]
hsa-miR-616-5pUrine127Up[86]
hsa-miR-619-5pUrine140Up[72]
hsa-miR-628-5pUrine140Up[72]
hsa-miR-636Urine2232Up[81]
hsa-miR-638Urine140UP[72]
hsa-miR-640Urine127Up[86]
hsa-miR-645Urine127Up[86]
hsa-miR-665Urine127Down[86]
hsa-miR-6809-5p Urine26 Down [69]
hsa-miR-6831-5p Urine26 Up [69]
hsa-miR-760Urine26 Up [77]
hsa-miR-765Urine140UP[72]
hsa-miR-767-3pUrine127Down[86]
hsa-miR-770-5pUrine127Up[86]
hsa-miR-7846-3p Urine26 Up [69]
hsa-miR-877-3pUrine280Up[80]
hsa-miR-92a-3pUrine148 + 40Up/Down[68,72]
hsa-miR-92b-5pUrine140UP[72]
hsa-miR-93-5pUrine2160Up[71]
hsa-miR-98-3p Blood/Urine227 Down [66]
hsa-miR-99b-5pUrine148Up[68]
hsa-miR-99b-5p Blood/Urine227Down [66]
miRNAs are annotated as a mature sequence of miRNA identified from the miRbase database. NC: not changed. miRNA in bold indicates differentially expressed direction between publications.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, C.-C.; Chen, C.-C.; Hsu, C.-K.; Chen, Y.-T.; Chen, C.-Y.; Yang, K.-J.; Hung, M.-J.; Wu, I.-W. Urinary microRNA in Diabetic Kidney Disease: A Literature Review. Medicina 2023, 59, 354. https://doi.org/10.3390/medicina59020354

AMA Style

Lee C-C, Chen C-C, Hsu C-K, Chen Y-T, Chen C-Y, Yang K-J, Hung M-J, Wu I-W. Urinary microRNA in Diabetic Kidney Disease: A Literature Review. Medicina. 2023; 59(2):354. https://doi.org/10.3390/medicina59020354

Chicago/Turabian Style

Lee, Chin-Chan, Chia-Chun Chen, Cheng-Kai Hsu, Yih-Ting Chen, Chun-Yu Chen, Kai-Jie Yang, Ming-Jui Hung, and I-Wen Wu. 2023. "Urinary microRNA in Diabetic Kidney Disease: A Literature Review" Medicina 59, no. 2: 354. https://doi.org/10.3390/medicina59020354

Article Metrics

Back to TopTop